Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $0M | $-532M | $-506M | $-407M | -59.3% | - | 22.2% |
| 2025 | $0M | $-438M | $-414M | $-377M | -58.5% | - | 59.6% |
| 2024 | $0M | $-270M | $-259M | $-215M | -42.0% | - | 22.9% |
| 2023 | $0M | $-208M | $-211M | $-188M | -58.2% | - | - |
| 2022 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2026 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 532.90 |
| Research And Development | 456.66 |
| Selling General And Administration | 76.24 |
| Total Expenses | 532.90 |
| Operating Income | -532.90 |
| EBITDA | -532.49 |
| Normalized EBITDA | -532.49 |
| EBIT | -532.90 |
| Interest Income | 25.33 |
| Net Interest Income | 25.33 |
| Other Non Operating Income Expenses | 2.18 |
| Other Income Expense | 2.18 |
| Interest Income Non Operating | 25.33 |
| Net Non Operating Interest Income Expense | 25.33 |
| Pretax Income | -505.39 |
| Tax Provision | 0.22 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -505.61 |
| Net Income From Continuing And Discontinued Operation | -505.61 |
| Net Income From Continuing Operation Net Minority Interest | -505.61 |
| Net Income | -505.61 |
| Net Income Common Stockholders | -505.61 |
| Net Income Including Noncontrolling Interests | -505.61 |
| Normalized Income | -505.61 |
| Diluted NI Availto Com Stockholders | -505.61 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 0.41 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Restructuring And Mergern Acquisition | 0 |
| General And Administrative Expense | 76.24 |
| Other Gand A | 76.24 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Immunovant, Inc.this co. | IMVT | $6.7B | -13.27 | 7.87 | -59.3% | -10.90 |
| HealthEquity, Inc. | HQY | $7.2B | 33.42 | 3.41 | 10.2% | 16.10 |
| Oscar Health, Inc. | OSCR | $7.1B | -16.06 | 7.28 | -45.3% | - |
| Vaxcyte, Inc. | PCVX | $7.0B | -9.18 | 2.62 | -28.5% | -7.77 |
| Apogee Therapeutics, Inc. | APGE | $6.9B | -26.79 |
| - |
| - |
| - |
| 7.58 |
| -28.3% |
| -23.68 |
| Spyre Therapeutics, Inc. | SYRE | $6.8B | - | 9.53 | -21.7% | - |
| Arcellx, Inc. | ACLX | $6.7B | -29.41 | 16.73 | -56.9% | -30.17 |
| Lantheus Holdings, Inc. | LNTH | $6.7B | 28.66 | 6.14 | 21.4% | 17.23 |
| Hims & Hers Health, Inc. | HIMS | $6.5B | 50.51 | 11.99 | 23.7% | 46.06 |
| Peer Median | - | -9.18 | 7.43 | -25.0% | 4.16 | |